tiprankstipranks
Advertisement
Advertisement

PHAT Stock Latest News

Phathom Pharmaceuticals completes enrollment in pHalcon-EoE-201 clinical trial
The FlyPhathom Pharmaceuticals completes enrollment in pHalcon-EoE-201 clinical trial
3d ago
PHAT
Phathom Completes Enrollment in Eosinophilic Esophagitis Trial
PremiumCompany Announcements
Phathom Completes Enrollment in Eosinophilic Esophagitis Trial
3d ago
8K
PHAT
Analyst Reaffirms Buy on Phathom as Voquezna Momentum Builds; $28 Price Target Maintained
PremiumRatings
Analyst Reaffirms Buy on Phathom as Voquezna Momentum Builds; $28 Price Target Maintained
25d ago
PHAT
Needham pharmaceuticals analysts hold analyst/industry conference call
PremiumThe Fly
Needham pharmaceuticals analysts hold analyst/industry conference call
1M ago
PHAT
Phathom Shareholders Reaffirm Board, Pay and Auditor
PremiumCompany Announcements
Phathom Shareholders Reaffirm Board, Pay and Auditor
1M ago
8K
PHAT
Analyst Reiterates Buy on Phathom as Voquezna Strategy Advances; $28 Price Target Maintained
PremiumRatingsAnalyst Reiterates Buy on Phathom as Voquezna Strategy Advances; $28 Price Target Maintained
1M ago
PHAT
Phathom Pharmaceuticals Signals Strong Growth on Earnings Call
Premium
Company Announcements
Phathom Pharmaceuticals Signals Strong Growth on Earnings Call
2M ago
PHAT
Phathom Pharmaceuticals reports Q1 non-GAAP EPS (18c), consensus (19c)
Premium
The Fly
Phathom Pharmaceuticals reports Q1 non-GAAP EPS (18c), consensus (19c)
2M ago
PHAT
Phathom Pharmaceuticals still sees 2026 revenue $320M-$34M, consensus $332.04M
PremiumThe Fly
Phathom Pharmaceuticals still sees 2026 revenue $320M-$34M, consensus $332.04M
2M ago
PHAT
Phathom Pharmaceuticals upgraded to Overweight from Equal Weight at Barclays
PremiumThe Fly
Phathom Pharmaceuticals upgraded to Overweight from Equal Weight at Barclays
3M ago
PHAT
Phathom Pharmaceuticals management to meet with Cantor
PremiumThe Fly
Phathom Pharmaceuticals management to meet with Cantor
3M ago
PHAT
Phathom Pharmaceuticals Charts Profitable Path After Ramp-Up
PremiumCompany Announcements
Phathom Pharmaceuticals Charts Profitable Path After Ramp-Up
4M ago
PHAT
Phathom Pharmaceuticals price target raised to $25 from $20 at Guggenheim
PremiumThe FlyPhathom Pharmaceuticals price target raised to $25 from $20 at Guggenheim
4M ago
PHAT
Phathom Pharmaceuticals: Early VOQUEZNA Traction, Strengthened Balance Sheet, and Clear Path to Profitability Support Buy Rating
Premium
Ratings
Phathom Pharmaceuticals: Early VOQUEZNA Traction, Strengthened Balance Sheet, and Clear Path to Profitability Support Buy Rating
4M ago
PHAT
Phathom Pharmaceuticals price target raised to $13 from $12 at Goldman Sachs
Premium
The Fly
Phathom Pharmaceuticals price target raised to $13 from $12 at Goldman Sachs
4M ago
PHAT
Phathom Pharmaceuticals reports Q4 EPS (8c), consensus (19c)
PremiumThe Fly
Phathom Pharmaceuticals reports Q4 EPS (8c), consensus (19c)
4M ago
PHAT
Phathom Pharmaceuticals sees FY26 net revenues $320M9$345M, consensus $312.56M
PremiumThe Fly
Phathom Pharmaceuticals sees FY26 net revenues $320M9$345M, consensus $312.56M
4M ago
PHAT
Phathom Pharmaceuticals Announces $130 Million Public Offering
PremiumCompany Announcements
Phathom Pharmaceuticals Announces $130 Million Public Offering
6M ago
8K
PHAT
Phathom Pharmaceuticals 6.875M share Secondary priced at $16.00
PremiumThe Fly
Phathom Pharmaceuticals 6.875M share Secondary priced at $16.00
6M ago
PHAT
Closing Bell Movers: Defense stocks surge on Trump military budget comments
PremiumThe FlyClosing Bell Movers: Defense stocks surge on Trump military budget comments
6M ago
FC
GD
Phathom raises FY25 revenue view to $174.5M-$175.5M from $170M-$175M
Premium
The Fly
Phathom raises FY25 revenue view to $174.5M-$175.5M from $170M-$175M
6M ago
PHAT
Phathom Pharmaceuticals announces common stock offering, no amount given
Premium
The Fly
Phathom Pharmaceuticals announces common stock offering, no amount given
6M ago
PHAT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >